Cystic fibrosis drug Orkambi ‘too pricey for the NHS’
- Only around half of people with cystic fibrosis live to see 40th birthday
- Drug named Orkambi has the potential to add years to someone’s life
- It has been shown to improve lung function and respiratory symptoms
- But Orkambi costs £104,000 per patient for every year of treatment
Daily Mail Reporter
8
View
comments
Almost 3,000 people with cystic fibrosis will miss out on a ‘breakthrough’ treatment after the health watchdog turned it down for use on the NHS.
The National Institute for Health and Care Excellence (Nice) rejected the drug Orkambi, which has been shown in clinical trials to improve lung function and respiratory symptoms in people with the genetic condition.
The charity the Cystic Fibrosis Trust said that since Nice undertook its appraisal, new data had been published that suggested Orkambi almost halved the rate of decline in lung function in people with the disease over a two-year period, potentially adding years to life.
Orkambi costs £104,000 per patient for every year of treatment and Professor Carole Longson, director of the Nice centre for health technology evaluation, said that ‘is too high’
Only around half of people with cystic fibrosis live to celebrate their 40th birthday.
The drug, which is approved in the US, Germany and France, is for people with the F508del mutation, which causes the production of an abnormal protein that disrupts how water and chloride are transported in the body.
Having two copies of this mutation (one inherited from each parent) is the leading cause of cystic fibrosis.
Ed Owen, chief executive of the Cystic Fibrosis Trust, said: ‘We are very disappointed by this decision.
-
Patients hit by big bills to fix shoddy dental work: Number…
Fraud doctor is told to repay £75,000 or face two years in…
Football player, 17, among three killed after small six-seat…
An instant heart scan? Use a smartphone: Surgeries to get…
‘It demonstrates the weakness of the current system, and Nice has been unable to confidently predict the long-term benefits of the drug.
‘However, new data published last month shows the positive impact of Orkambi over a two-year period to slow the decline in lung health. Our Cystic Fibrosis Registry offers additional means to collect real-world evidence while ensuring people with cystic fibrosis have access to the first therapy that tackles the underlying cause of the condition for almost 3,000 people.’
Simon Bedson, senior vice president at Vertex, which makes the drug, said it was now in talks with the Department of Health to agree a price that might make the drug accessible.
The Cystic Fibrosis trust wants to use its registry to see how the drug performs in a real-world setting.
The National Institute for Health and Care Excellence (Nice) rejected the drug Orkambi, which has been shown in clinical trials to improve lung function and respiratory symptoms (file photo)
Mr Bedson said: ‘As we’ve said for many months, the single technology appraisal process (used by Nice) is not appropriate for assessing medicines, such as Orkambi, for rare diseases like cystic fibrosis.
‘Vertex has submitted an access scheme to the Department of Health, and we urge the NHS and the Government to consider this proposal.’
Orkambi costs £104,000 per patient for every year of treatment.
Professor Carole Longson, director of the Nice centre for health technology evaluation, said: ‘We know how important a new treatment option would be for people with cystic fibrosis; but for the benefits it offers, the cost of Orkambi is too high.
‘We can only recommend treatments when we are certain they are both clinically effective and represent good value for money.
‘If the company is able to put forward a proposal that provides Orkambi at a cost-effective price, we would welcome it.’
Share or comment on this article
-
Video shows inside Pulse bathroom as killer stalked club
-
Antisocial dog ignores canine swimming pandemonium around…
-
WARNING: Man captured his own murder in graphic Facebook…
-
‘Alligator’ seen by Disney Orlando visitor days before…
-
Graphic bodycam video shows MMA fighter’s paralysis
-
Student mocks Donald Trump in epic presidential graduation…
-
Girl spontaneously dances to beautiful music from violinist
-
Woman runs down boyfriend ‘after he revealed he had HIV’
-
Epic fight to the death between tiger and leopard in reserve
-
Video shows arrest of alleged suspect in shooting of MP Jo…
-
Fox News TV presenter accidentally flashes UNDERWEAR
-
More cell phone video from inside Pulse bathroom as people…
-
Jo Cox’s devastated colleagues break down in tears as…
-
EXCLUSIVE: OJ Simpson WILL take a paternity test for Khloe…
-
Mom shares eerie photos of her son paddling on Disney beach…
-
Sore loser Steph? Curry throws tantrum in NBA Finals,…
-
PICTURED: Boy, two, who was found dead at the bottom of…
-
‘I love you babe’: Text messages Omar Mateen and his wife…
-
Best Buy worker gunman who shot dead Voice star Christina…
-
EXCLUSIVE: ‘There was no monogamy in the Kennedy clan.’…
-
EXCLUSIVE – ‘Why shouldn’t we enjoy ourselves just because…
-
The two massive and mysterious Texas sinkholes on the verge…
-
‘Four years?’: American father-of-two stabs himself to death…
-
Devastating cell phone video shows club-goers hiding out in…
Comments (8)
Share what you think
-
Newest -
Oldest -
Best rated -
Worst rated
The comments below have not been moderated.
The views expressed in the contents above are those of our users and do not necessarily reflect the views of MailOnline.
Find out now